Cargando…

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients

Detalles Bibliográficos
Autores principales:	Kaiser, Robert A., Haller, Maria C., Apfalter, Petra, Kerschner, Heidrun, Cejka, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276570/ https://www.ncbi.nlm.nih.gov/pubmed/34270945 http://dx.doi.org/10.1016/j.kint.2021.07.004

Ejemplares similares

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
por: Haller, Maria C., et al.
Publicado: (2022)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
por: Karatas, Elif, et al.
Publicado: (2022)

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
por: Yau, Kevin, et al.
Publicado: (2022)

Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
por: Xia, Xuhua
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273: Various toxicities: 13 case reports
Publicado: (2021)

Différences d’immunogénicité des vaccins anti-SRAS-CoV-2 mRNA-1273 (Moderna) et BNT162b2 (Pfizer-BioNTech) chez les patients dialysés
por: Yau, Kevin, et al.
Publicado: (2022)

COVID 19 Vaccine Pfizer BioNTech/mRNA-1273/ravulizumab: Various toxicities: 5 case reports
Publicado: (2021)

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report
por: Yangi, Kivanc, et al.
Publicado: (2023)

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
por: Walton, Muireann, et al.
Publicado: (2023)

Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
por: Inoue, Masatoshi, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
por: Akiyama, Yutaro, et al.
Publicado: (2023)

Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19
por: Khan, Farooq, et al.
Publicado: (2021)

The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers
por: Khuc, Thao A, et al.
Publicado: (2023)

Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273: IgA nephropathy and reactivation of glomerulonephritis: 4 case reports
Publicado: (2021)

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
por: Aldén, Markus, et al.
Publicado: (2022)

Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study
por: Patel, Prisha, et al.
Publicado: (2023)

Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose
por: Tuong, Linh-An C, et al.
Publicado: (2021)

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
por: Yong, Shin-Jie, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines
por: Noor, Rashed
Publicado: (2021)

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination
por: Kimura, Motoya, et al.
Publicado: (2022)

TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: A case report()
por: Yamada, Maaya, et al.
Publicado: (2022)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
por: Amblard, M.A., et al.
Publicado: (2022)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick D. M. C., et al.
Publicado: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick DMC., et al.
Publicado: (2023)

Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by COVID-19 mRNA Vaccine (Pfizer-BioNTech, BNT162b2): A Case Report and Literature Review
por: Kim, Ji Hyoun, et al.
Publicado: (2023)

A case of membranous nephropathy following Pfizer–BioNTech mRNA vaccination against COVID-19
por: Da, Yi, et al.
Publicado: (2021)

COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated
por: Lazarinis, Nikolaos, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

443. Pre-vaccination Antibody Titers Against Seasonal Coronaviruses And Antibody Responses to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA Vaccine in Healthcare Workers
por: Laing, Eric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gu7m1ce18tkdil9altl31ng6km